Reduction of Unnecessary Biopsies
According to the American College of Radiology (ACR), ten out of every 100 women who get a screening mammogram will be asked to return for additional screening. About 2% of those who return will undergo a needle biopsy1, and up to 85% of those biopsies will be benign.2 In fact, about $4 billion is spent annually in the U.S. on mammography false positives however, mammography is the only screening study shown in randomized clinical trials to decrease breast cancer mortality.3
CureMetrix AI for mammography demonstrates dramatic potential to vastly reduce unnecessary biopsies while decreasing unnecessary costs. In a recent study with MD Anderson Cancer Center, 48% of the cases studied had no markings at all from the CureMetrix AI-based CAD cmAssist; and had radiologists used cmAssist, they could have potentially reduced recalls by 69% over traditional CAD.4
Ultimately, decreasing the unnecessary biopsies is more cost effective for the healthcare system and decreases patient anxiety about breast cancer screening. Additionally, studies show that false-positive findings on screening mammography cause long-term psychosocial harm to the patient.5
ACR Follow-Up Testing Risks of Mammography Screening
